18.00
price down icon3.23%   -0.60
after-market アフターアワーズ: 18.00
loading
前日終値:
$18.60
開ける:
$19
24時間の取引高:
24,340
Relative Volume:
0.37
時価総額:
$929.11M
収益:
-
当期純損益:
$-143.59M
株価収益率:
-6.3748
EPS:
-2.8236
ネットキャッシュフロー:
$-119.47M
1週間 パフォーマンス:
+2.27%
1か月 パフォーマンス:
+7.27%
6か月 パフォーマンス:
-6.40%
1年 パフォーマンス:
+8.11%
1日の値動き範囲:
Value
$17.05
$19.00
1週間の範囲:
Value
$16.72
$19.00
52週間の値動き範囲:
Value
$11.51
$25.50

Pharvaris Nv Stock (PHVS) Company Profile

Name
名前
Pharvaris Nv
Name
セクター
Healthcare (1164)
Name
電話
-
Name
住所
-
Name
職員
119
Name
Twitter
Name
次回の収益日
2024-08-05
Name
最新のSEC提出書
Name
PHVS's Discussions on Twitter

PHVS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
PHVS
Pharvaris Nv
18.00 929.11M 0 -143.59M -119.47M -2.8236
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.41 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
538.11 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.13 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
546.04 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
240.99 28.51B 3.81B -644.79M -669.77M -6.24

Pharvaris Nv Stock (PHVS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-06-11 開始されました Guggenheim Buy
2025-04-29 開始されました Cantor Fitzgerald Overweight
2023-09-25 開始されました Wedbush Outperform
2023-08-15 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-10-05 開始されました Bryan Garnier Buy
2022-09-13 再開されました JMP Securities Mkt Outperform
2022-08-23 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-08-22 ダウングレード BofA Securities Neutral → Underperform
2022-05-25 開始されました JMP Securities Mkt Outperform
2021-03-02 開始されました BofA Securities Neutral
2021-03-02 開始されました Morgan Stanley Overweight
2021-03-02 開始されました Oppenheimer Outperform
2021-03-02 開始されました SVB Leerink Outperform
すべてを表示

Pharvaris Nv (PHVS) 最新ニュース

pulisher
Jun 16, 2025

(PHVS) Trading Advice - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Pharvaris presents new data on oral angioedema treatment at EAACI By Investing.com - Investing.com UK

Jun 16, 2025
pulisher
Jun 16, 2025

Clinical Trial Results: Revolutionary Oral HAE Drug Prevents Attacks and Improves Quality of Life in 97.8% of Patients - Stock Titan

Jun 16, 2025
pulisher
Jun 14, 2025

Analysts Set Pharvaris (NASDAQ:PHVS) Price Target at $36.20 - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

Pharvaris (NASDAQ:PHVS) Now Covered by Analysts at Guggenheim - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Weighs in on Pharvaris FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Pharvaris (PHVS) Gains Buy Rating with Promising Market Potentia - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Bank of America Corp DE Increases Stake in Pharvaris (NASDAQ:PHVS) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Guggenheim Initiates Coverage on Pharvaris With Buy Rating, $32 Price Target - marketscreener.com

Jun 11, 2025
pulisher
Jun 11, 2025

Pharvaris (PHVS) Receives New Buy Rating and $32 Target from Gug - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Millennium Management LLC Trims Stake in Pharvaris (NASDAQ:PHVS) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Pharvaris Schedules Key Shareholder Meeting: What HAE Treatment Investors Should Know - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 14,838 Shares of Pharvaris (NASDAQ:PHVS) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

What is Leerink Partnrs’ Forecast for Pharvaris Q2 Earnings? - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Pharvaris (NASDAQ:PHVS) Given “Outperform” Rating at Wedbush - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Pharvaris (PHVS) Receives Continued "Outperform" Rating from Wedbush | PHVS Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Pharvaris (PHVS) Receives Continued "Outperform" Rating from Wed - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Citizens JMP reiterates Market Outperform rating for Pharvaris stock By Investing.com - Investing.com UK

Jun 05, 2025
pulisher
Jun 04, 2025

Transcript : Pharvaris N.V.Special Call - marketscreener.com

Jun 04, 2025
pulisher
Jun 02, 2025

Pharvaris (PHVS) Spotlights Promising Deucrictibant Data at Key Workshop | PHVS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Pharvaris reports promising results for deucrictibant in HAE By Investing.com - Investing.com UK

Jun 02, 2025
pulisher
Jun 01, 2025

Pharvaris (NASDAQ:PHVS) Shares Acquired by Deutsche Bank AG - Defense World

Jun 01, 2025
pulisher
May 27, 2025

Northern Trust Corp Purchases 76,188 Shares of Pharvaris (NASDAQ:PHVS) - Defense World

May 27, 2025
pulisher
May 24, 2025

How To Trade (PHVS) - news.stocktradersdaily.com

May 24, 2025
pulisher
May 20, 2025

Cubist Systematic Strategies LLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS) - Defense World

May 20, 2025
pulisher
May 19, 2025

New Clinical Data Reveals Long-Term Success of Oral HAE Treatment Deucrictibant - Stock Titan

May 19, 2025
pulisher
May 18, 2025

Pharvaris (NASDAQ:PHVS) Shares Gap Down – Here’s What Happened - Defense World

May 18, 2025
pulisher
May 18, 2025

Brokers Offer Predictions for Pharvaris FY2025 Earnings - Defense World

May 18, 2025
pulisher
May 17, 2025

Q2 Earnings Forecast for Pharvaris Issued By Leerink Partnrs - Defense World

May 17, 2025
pulisher
May 17, 2025

Cantor Fitzgerald Cuts Pharvaris (NASDAQ:PHVS) Price Target to $25.00 - Defense World

May 17, 2025
pulisher
May 17, 2025

Research Analysts Issue Forecasts for Pharvaris Q2 Earnings - Defense World

May 17, 2025
pulisher
May 16, 2025

Pharvaris (NASDAQ:PHVS) Holdings Decreased by Barclays PLC - Defense World

May 16, 2025
pulisher
May 15, 2025

The Manufacturers Life Insurance Company Reduces Stake in Pharvaris (NASDAQ:PHVS) - Defense World

May 15, 2025
pulisher
May 15, 2025

Pharvaris (NASDAQ:PHVS) Shares Down 5.1% on Disappointing Earnings - Defense World

May 15, 2025
pulisher
May 14, 2025

Transcript : Pharvaris N.V. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

PHVS Reports Decrease in Cash Reserves by March Quarter End | PH - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Pharvaris (PHVS) Target Price Revised by Cantor Fitzgerald | PHV - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Pharvaris (PHVS) Target Price Increased by Wedbush Amid Clinical Progress | PHVS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Wedbush Adjusts Pharvaris Price Target to $17 From $25, Maintains Outperform Rating - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

(PHVS) Long Term Investment Analysis - news.stocktradersdaily.com

May 14, 2025
pulisher
May 13, 2025

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Pharvaris Hits Major FDA Milestone for HAE Drug Pipeline While Phase 3 Trials Show Strong Progress - Stock Titan

May 13, 2025
pulisher
May 13, 2025

Pharvaris (PHVS) Expected to Announce Earnings on Wednesday - Defense World

May 13, 2025
pulisher
May 12, 2025

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4 - Stock Titan

May 12, 2025
pulisher
May 07, 2025

Pharvaris (NASDAQ:PHVS) Shares Acquired by JPMorgan Chase & Co. - Defense World

May 07, 2025
pulisher
May 03, 2025

When (PHVS) Moves Investors should Listen - news.stocktradersdaily.com

May 03, 2025
pulisher
May 02, 2025

Pharvaris NV expected to post a loss of 76 cents a shareEarnings Preview - TradingView

May 02, 2025
pulisher
May 02, 2025

Geode Capital Management LLC Has $735,000 Stock Position in Pharvaris (NASDAQ:PHVS) - Defense World

May 02, 2025
pulisher
May 02, 2025

Pharvaris (NASDAQ:PHVS) Holdings Increased by Legal & General Group Plc - Defense World

May 02, 2025
pulisher
May 02, 2025

Analysts Offer Predictions for Pharvaris FY2025 Earnings - Defense World

May 02, 2025
pulisher
May 02, 2025

Pharvaris (NASDAQ:PHVS) Research Coverage Started at Cantor Fitzgerald - Defense World

May 02, 2025

Pharvaris Nv (PHVS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.52
price up icon 1.08%
$35.59
price down icon 2.14%
$22.61
price down icon 7.90%
$96.95
price down icon 0.87%
$110.05
price up icon 0.05%
biotechnology ONC
$240.99
price down icon 1.83%
大文字化:     |  ボリューム (24 時間):